Tubulis

(IN BRIEF) EQT Life Sciences has exited its investment in Tubulis following Gilead Sciences’ agreement to acquire the German biotechnology company in a deal valued at up to $5 billion including milestones. EQT supported Tubulis’ development into a clinical-stage oncology … Read the full press release →

(IN BRIEF) Tubulis has been named one of 2024’s “Fierce 15” biotechnology companies by Fierce Biotech. This recognition celebrates Tubulis’ innovative work in ADC development and its commitment to improving cancer treatment outcomes. With significant recent advancements, including a €128 … Read the full press release →

(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release →